| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold | | | | | Pharmaceutical | | | | | | | | | | | and | | | | | | | | | Dermatology | | Biotechnology | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | Three Months Ended June 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 4,054 | | $ | 350 | | $ | 46,293 | | $ | 50,697 | | | Direct cost of goods | | | (878) | | | - | | | - | | | (878) | | | Sales and marketing costs | | | (2,610) | | | - | | | - | | | (2,610) | | | Research and development | | | - | | | (13,483) | | | - | | | (13,483) | | | General and administrative | | | (293) | | | (8,231) | | | - | | | (8,524) | | | National Expenses | | | - | | | - | | | (48,395) | | | (48,395) | | | Segment loss from operations | | $ | 273 | | $ | (21,364) | | $ | (2,102) | | $ | (23,193) | | | Segment assets | | $ | 5,447 | | $ | 167,787 | | $ | 76,612 | | $ | 249,846 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Three Months Ended June 30, 2016 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | 982 | | $ | 1,248 | | $ | 2,230 | | | Direct cost of goods | | | (324) | | | - | | | (324) | | | Sales and marketing costs | | | (1,998) | | | - | | | (1,998) | | | Research and development | | | - | | | (8,407) | | | (8,407) | | | General and administrative | | | - | | | (6,637) | | | (6,637) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (1,340) | | $ | (13,796) | | $ | (15,136) | | | Segment assets | | $ | 3,058 | | $ | 95,004 | | $ | 98,062 | | | | | | | Pharmaceutical | | | | | | | | | | | and | | | | | | | | | Dermatology | | Biotechnology | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | Six Months Ended June 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 6,139 | | $ | 1,043 | | $ | 88,197 | | $ | 95,379 | | | Direct cost of goods | | | (1,347) | | | - | | | - | | | (1,347) | | | Sales and marketing costs | | | (4,877) | | | - | | | - | | | (4,877) | | | Research and development | | | - | | | (21,887) | | | - | | | (21,887) | | | General and administrative | | | (612) | | | (15,897) | | | - | | | (16,509) | | | National Expenses | | | - | | | - | | | (91,529) | | | (91,529) | | | Segment loss from operations | | $ | (697) | | $ | (36,741) | | $ | (3,332) | | $ | (40,770) | | | Segment assets | | $ | 5,447 | | $ | 167,787 | | $ | 76,612 | | $ | 249,846 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology | | | | | Six Months Ended June 30, 2016 | | Sales | | Product Development | | Consolidated | | | Net Revenue | | $ | 1,364 | | $ | 1,526 | | $ | 2,890 | | | Direct cost of goods | | | (324) | | | - | | | (324) | | | Sales and marketing costs | | | (3,884) | | | - | | | (3,884) | | | Research and development | | | - | | | (16,243) | | | (16,243) | | | General and administrative | | | - | | | (12,666) | | | (12,666) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (2,844) | | $ | (27,383) | | $ | (30,227) | | | Segment assets | | $ | 3,058 | | $ | 95,004 | | $ | 98,062 | |
|